Vesugen
Vesugen, a peptide. Synthetic tripeptide Lys-Glu-Asp from the Khavinson short-peptide programme, assigned to vascular tissue. The trade name is equated with the…
Synthetic tripeptide Lys-Glu-Asp from the Khavinson short-peptide programme, assigned to vascular tissue. The trade name is equated with the sequence by PMID:22808515 verbatim: "The expression of differentiation factors CXCL12, Hoxa3, and WEGC1 was tissue-specifically stimulated by short peptides: pancragen (Lys-Glu-Asp-Trp) in pancreatic cells, bronchogen (Ala-Glu-Asp-Leu) in bronchial epithelial cells, and vesugen (Lys-Glu-Asp) in fibroblasts." The proposed vascular mechanism is transcriptional — PMID:28539025 verbatim, "KED peptide has normalized endothelin-1 expression, which increased during atherosclerosis and restenosis. KED peptide also restorates cells interactions by connexin expression." All of that is human cells in vitro. NO RECEPTOR IS NAMED AND NOTHING HERE IS EXPRESSIBLE AS AN OCCUPANCY ROW.
MASS WARRANT. PubChem has NO entry under the trade name "Vesugen" (PUGREST.NotFound, 2026-09-26); the mass comes from the SEQUENCE, Lys-Glu-Asp = CID 87571363 (C15H26N4O8, 390.39, CAS 204271-66-9, CHEBI:159909), and the warrant for attaching it to this record is the PMID:22808515 sentence quoted in `mechanism` that equates vesugen with Lys-Glu-Asp. Without that sentence the mass would not be storable here. HUMAN DATA EXIST AND CARRY A SAFETY SIGNAL WORTH KEEPING. PMID:26390612 verbatim: "32 people (18 men, 12 women) aged 41-83 years with polymorbidity and the organic brain syndrome in remission participated in the study. … have had the significant anabolic effect." The SAME abstract reports harm: "At the same time we have found the prooxidant activity through chemiluminescence. Decrease of markers CD34+ positive hematopoietic polypotent cells in blood has shown significant inhibition of hemopoiesis." A grey-market peptide whose one human study reports inhibited haematopoiesis is exactly the kind of record this catalog should carry, so the negative finding is on the record and not buried. NOTE the study is co-administration with Pinealon, already in this catalog, so neither effect is attributable to this peptide alone. The 2021 Alzheimer review PMID:34173097 is a REVIEW and is cited only for the route claim, never for a number. THE ROUTE IS REVIEW-SOURCED, NOT MEASURED: the only statement of one is PMID:34173097, a review — "Oral application of KED (Lys-Glu-Asp) improved memory and attention in elderly individuals with functional CNS disorders". It is cited for the route claim and never for a number.
Sources: PMID:22808515, PMID:28539025, PMID:26390612, PMID:34173097